Healthcare organizations looking to implement low dose protocols for computed tomography (CT) exams on all scanners, regardless of disparate locations, can now benefit from SafeCT Enterprise from Medic Vision. The solution will be displayed at RSNA 2014.

CardioDx Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a Gene Expression Score Showed Clinical Utility in Evaluating African Americans Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease in a Primary Care Practice," at the 36th annual North American Meeting of the Society for Medical Decision Making, taking place from Oct. 18-22 in Miami.

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. The Promus Premier stent system is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor, M.D., FACC, FSCAI, and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Fla.

Boston Scientific Corp. has received CE mark approval for the Accolade pacemaker family.

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. At least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association.